Medicines don’t fail because of molecules. They fail because of delivery.
Ibumix is engineering a new generation of liquid crystal-based excipient systems — designed to improve absorption, eliminate formulation variability, and realise the full therapeutic potential of every dose.
Oral medicines are limited not by their active ingredients, but by how effectively they are absorbed.
A significant proportion of each dose is lost before it can have a therapeutic effect.
This inefficiency is built into modern medicine.
The next frontier is not the molecule
Pharmaceutical innovation has focused on discovering new compounds.
The next step-change in performance comes from how those compounds are delivered.
A new formulation paradigm
Advanced Formulation Engineering
Designed to enhance solubility and absorption
Next-Generation Excipients
Engineered to improve delivery efficiency
Bioavailability Optimisation
Faster, simpler dosing
A platform, not a product
Ibumix is building formulation platforms with applications across multiple active pharmaceutical ingredients and therapeutic areas.
Ibuprofen and naproxen are the starting points.
The opportunity extends far beyond it.
Science led, data driven
Our approach is grounded in rigorous formulation science and supported by structured research and development.
Early-stage programmes are focused on generating high-quality data to validate performance and guide optimisation.
Building the future of drug delivery
Ibumix is currently engaging with investors to support its next phase of development.
Explore the platform
Four ideas sit beneath everything Ibumix builds — and one platform ties them together.